| P50 | author | Edward Thorp | Q41305505 |
| P2860 | cites work | MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation | Q37183630 |
| | An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques | Q37282266 |
| | Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice | Q39649085 |
| | Resolving Lipid Mediators Maresin 1 and Resolvin D2 Prevent Atheroprogression in Mice | Q49112867 |
| | Annexin A1 counteracts chemokine-induced arterial myeloid cell recruitment. | Q53665256 |
| | Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy | Q68182877 |
| | The response-to-retention hypothesis of early atherogenesis | Q24629974 |
| | Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis | Q28236868 |
| | Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis | Q34162546 |
| | Proresolving lipid mediators and mechanisms in the resolution of acute inflammation | Q34411426 |
| | Nutrigenetic disruption of inflammation-resolution homeostasis and atherogenesis | Q34829161 |
| | Resolvin E1 (RvE1) Attenuates Atherosclerotic Plaque Formation in Diet and Inflammation-Induced Atherogenesis | Q35555554 |
| | Inflammation in atherosclerosis | Q36174933 |
| | Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators | Q36879456 |
| P433 | issue | 9 | |
| P304 | page(s) | 972-974 | |
| P577 | publication date | 2016-10-01 | |
| P1433 | published in | Circulation Research | Q2599020 |
| P1476 | title | Proresolving Lipid Mediators Restore Balance to the Vulnerable Plaque | |
| P478 | volume | 119 | |